top of page

Journal Articles

videoblocks-hex-particles-medical-grid-hexagon-pattern-technology-background-loop_slwe1kom

Disclaimer: The papers below are intended for private viewing by the page owner or those who otherwise have legitimate access to them. No part of it may in any form or by any electronic, mechanical, photocopying, recording, or any other means be reproduced, stored in a retrieval system or be broadcast or transmitted without the prior permission of the respective publishers. If your organization has a valid subscription of the journals, click on the DOI link for the legitimate copy of the papers.

View By Year Published

2018-2019

Raffa RB, Taylor R Jr, Pergolizzi JV Jr.

Treating opioid-induced constipation in patients taking other medications: Avoiding CYP450 drug interactions J Clin Pharm Ther 2019;44(3):361-371

Pergolizzi JV Jr., Rosenblatt M, Mariano DJ, LeQuang JA

Clinical considerations about opioid withdrawal symptoms Pain Manag 2019; 9(2):111-113

Pergolizzi JV, LeQuang JA, Passik S, Coluzzi F

Using opioid therapy for pain in clinically challenging situations: questions for clinicians Minerva Anesthesiol 2019; 85(8):899-908

 

Kitzen JM, McConaha JL, Bookser, ML, Pergolizzi JV Jr, Taylor R Jr, Raffa RB

E-cigarettes for smoking cessation: do they deliver? J Clin Pharm Ther 2019;44(4):650-655

 

Pergolizzi JV Jr, Rosenblatt M, LeQuang JA.

Three years down the road: the aftermath of the CDC guideline for prescribing opioids for chronic pain Adv Ther 2019;36(6):1235-1240

 

Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Lara A, Ortiz AH, Iban MAR

Pain Control in Latin America: The Optimized Role of Buprenorphine in the Treatment of Cancer and Noncancer Pain Pain. Pain Ther 8, 187–201 (2019)

 

Pergolizzi JV, Varrassi G, Paladini A, LeQuang J

Stopping of decreasing opioid therapy in patients on chronic opioid therapy Pain Ther. 2019 Dec;8(2):163-176

DOI:10.1007/s40122-019-00135-6

 

Varrassi G, Alon E, Bagnasco M, Lanata L, Mayoral-Royals V, Paladini A, Pergolizzi JV, Perrot S, Scarpignato C, Tolle T

Towards an effective and safe treatment of inflammatory pain: a Delphi-guided expert consensus Adv Ther 36, 2618–2637 (2019)

DOI:10.1007/s12325-019-01053-x

Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Bisney J

Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain Pain Ther 2018;7(1):37-57

 

Pergolizzi JV Jr., Taylor R, Jr., LeQuang JA, Bisney J. Raffa RB, Pergolizzi F, Colucci D, Batastini L

Driving under the influence of opioids: what prescribers should know J Opioid Manag 2018;14(6):415-427

 

Pergolizzi, J.V., Annabi, H., Gharibo, C., LeQuang, JA

The Role of Lofexidine in Management of Opioid Withdrawal Pain Ther 2019;8(1)67-78

 

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Parker G, Rodenbeck R

Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 3 – application of human factors engineering to an ozone hand sanitizer Pharmacol Pharm 2018;9:324-330

 

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Choudhuri S, Rodenbeck R

Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 2 – human factors Pharmacol Pharm 2018;9:310-323

 

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Choudhuri S, Rodenbeck R

Persistence of healthcare-associated (nosocomial) infections due to inadequate hand hygiene: Part 1 – biological and treatment factors Pharmacol Pharm 2018;9:293-309

 

Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Raffa RB

The Place of Community Rescue Naloxone in a Public Health Crisis of Opioid Overdose Pharmacol Pharm 2019, 10, 61-81

DOI:10.4236/pp.2019.102006

 

Nalamachu S, Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Pergolizzi JV 3rd, Raffa RB

Hormone replacement therapy for restoring the HPG axis in pain patients treated with long-term opioid analgesics Pharmacol Pharm 2018;9:473-480

 

Pergolizzi JV Jr, Ossipov MH, Taylor R Jr, Raffa RB

‘New-look’ opioids: biased ligands Pharmacol Pharm 2018;9:242-249

 

Pergolizzi JV Jr, Taylor R Jr, Raffa RB

Crisaborole and apremilast: pde4 inhibitors with similar mechanism of action, different indications for management of inflammatory skin conditions Pharmacol Pharm 2018;9:357-381

 

Raffa RB, Pergolizzi JV Jr, Taylor R Jr., James RP, Pirner M

Differences in the receptor binding profile of lofexidine compared to clonidine Pharmacology & Pharmacy, 2019, 10, 1-10

DOI:10.4236/pp.2019.101001

 

Ossipov MH, Pergolizzi JV Jr, Taylor R Jr, Raffa RB

Targets to watch – nerve growth factor (NGF) as a target for the treatment of neuropathic pain Drugs Future 2018;43:655-664

 

Raffa RB, Pergolizzi JV Jr, Taylor R Jr.

The fist approved ‘deuterated’ drug: a short review of the concept Pharmacol Pharm 2018;9:440-446

 

Kitzen JM, Pergolizzi JV Jr, Taylor R Jr, Raffa RB

The role of medical literature, clinical trials and experimental research in drug product-injury litigation: a primer with two examples Pharmacol Pharm 2018;9:208-227

 

Pergolizzi JV Jr, LeQuang JA, Bisney J

Cannabinoid Hyperemesis. Medical Cannabin and Cannabinoids Med Cannabis Cannabinoids 2018;1:73–95

DOI:10.1159/000494992

 

Pergolizzi J, Kowalski M, He E

Effectiveness of once-daily extended-release hydrocodone in individuals previously receiving immediate-release oxycodone for chronic pain Pain Med 2018;19(5):967-977

 

Raffa RB, Pergolizzi JV Jr, LeQuang JA, Taylor R Jr., Colucci S, Annabi MH

The fentanyl family: a distinguished medical history tainted by abuse J Clin Ther. 2018;43(1):154-158

 

Meissner W, Huygen F, Neugebauer EAM, Osterbrink J, Benhamou D, Betteridge N, Coluzzi F, De Andres J, Fawcett W, Fletcher D, Kalso E, Kehlet H, Morlion B, Montes Pérez A, Pergolizzi J, Schäfer M

Management of acute pain in the postoperative setting: the importance of quality indicators Curr Med Res Opin 2018; 34(1):187-196

 

Raffa RB, Pergolizzi JV Jr, Taylor R Jr

The rapid-onset antidepressant effect of ketamine: More surprises? J Clin Pharm Ther 2018;43(2):308-311

 

Pergolizzi JV Jr, LeQuang JA, Taylor R, Raffa RB

Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances and street heroin Postgrad Med 2018. 130(1):1-8

Raffa RB, Pawasauskas J, Pergolizzi JV Jr, Lu L, Chen Y, Wu S, Jarrett B, Fain R, Hill L, Devarakonda K

Pharmacokinetics of oral and intravenous paracetamol (acetaminophen) when co-administered with intravenous morphine in healthy adult subjects Clin Drug Investig. 2018. 38(3):259-268

Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Vacalis S

Abuse-deterrent opioids: an update on current approaches and considerations Curr Med Res Opin 2018;34(4):711-723

Pergolizzi JV J, LeQuang JA, Taylor R Jr, Raffa RB, Colucci D

The role of cannabinoids in pain control: the good, the bad, and the ugly Minerva Anestesiol 2018 84(8):955-969

Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release products J Pain Res. 2018;11:301-311

Morlion B, Coluzzi F, Aldington D, Kocot-Kepska M, Pergolizzi J, Mangas AC, Ahlbeck K, Kalso E

Pain chronification: what should a non-pain specialist know? Curr Med Res Opin 2018; 34(7):1169-1178

Raffa RB, Pergolizzi JV, Taylor R, Ossipov MH

Nature’s first atypical opioids: kratom and mitragynines J Clin Pharm Ther 2018;43(3):437-441

Pergolizzi JR JV, Taylor R Jr, LeQuang JA, Raffa RB

The role and mechanism of action of menthol in topical analgesic products J Clin Pharm Ther 2018; 43(3):313-319

Pergolizzi JV Jr, Taylor R Jr, LeQuang JA, Raffa RB, Bisney J

Tapentadol extended release in the treatment of severe chronic low back pain and osteoarthritis pain Pain Ther 2018; 7(1):37-57

Pergolizzi JV Jr, Coluzzi F, Taylor R Jr

Transdermal buprenorphine for moderate chronic noncancer pain syndromes Expert Rev Neurother 2018; 23:1-11

Raffa RB, Pergolizzi JV Jr, Taylor R Jr., Ossipov MH

Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs) J Clin Pharm Ther. 2018 Aug;43(4):443-449.

DOI:10.1111/jcpt.12687

Eke-Okoro UJ, Raffa RB, Pergolizzi JV Jr, Breve F, Taylor R Jr.

Curcumin in turmeric: basic and clinical evidence for a potential role in analgesia J Clin Pharm Ther 2018. 43(4):460-464

Pergolizzi JV Jr, Taylor R JR, LeQuang JA, Raffa RB.

What’s holding back abuse-deterrent opioid formulations? Considering 12 US stakeholders Exp Opin Drug Deliv 2018; 15(6):567-576

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Ossipov MH

Discovery of folded DNA structures in human cells: potential drug targets J Clin Pharm Ther 2019; 44(1):125-128

DOI:10.1111/jcpt.12758

Pergolizzi JV Jr, LeQuang JA, Taylor R Jr, Ossipov MH, Colucci D, Raffa RB

Designing safer analgesics: a focus on µ opioid receptor pathways Exp Opin Drug Discov 2018; 13(10)965-972

Pergolizzi JV , Rosenblatt M, Mariano DJ, Bisney J

Tapering opioid therapy: clinical strategies Pain Manag 2018;8(6):409-413

Raffa RB, Pergolizzi JV Jr, Taylor R Jr, Kitzen JM

Sunscreen bans: coral reefs and skin cancer J Clin Pharm Ther. 2018; 44(1):134-139

DOI:10.1111/jcpt.12778

bottom of page